Testing for MRD can shape treatment choices and overall patient management to achieve better outcomes. Unfortunately, routine MRD testing is variable, and there are currently no standards for optimal MRD testing. To help address this deficiency, ACCC is conducting an educational project to create tools and recommend effective practices that multidisciplinary providers can use to successfully integrate MRD testing into their cancer care continuum—specifically for patients with B-cell acute lymphoblastic leukemia (ALL).
The project will provide information and guidance to members of multidisciplinary cancer care teams, including pathologists, oncologists, advanced practice providers, pharmacists, social workers, financial advocates, administrators, IT professionals, policy analysts, and other relevant specialists.
B-cell ALL was the first disease state with an FDA-approved treatment for MRD. This project will help lay the foundation for MRD testing in patients with B-cell ALL to create better-informed multidisciplinary cancer care teams. Ultimately, this work will showcase not only the importance of MRD testing, but also how it can be best integrated into the cancer care workflow.
Specifically, this project will:
For more information about the project, please contact Mary Stanley, MSW, PMP, Program Manager, ACCC Provider Education.
Gain important and practical information for the assessment of measurable residual disease as part of routine clinical practice for patients with chronic lymphocytic leukemia (CLL).
Learn about the basics of MRD testing and how to assess your program’s buy-in to implement or expand MRD testing.
Learn how clinical and non-clinical staff are involved in MRD testing, how to assess your program’s communication and staffing needs, and how to develop an implementation plan.
Learn how to assess your clinical workflow needs to implement MRD testing and how to evaluate, pilot, and refine MRD testing in your program.